VIJOICE 125 mg/1 (Alpelisib TABLET) 125 mg/1

VIJOICE 125 mg/1 is an oral tablet containing alpelisib, a medication used to manage certain conditions. This product is manufactured by Novartis Pharmaceuticals Corporation in the USA.

Strength

125 mg/1

Pack Size

1 BLISTER PACK in 1 CARTON (0078-1028-91) / 28 TABLET in 1 BLISTER PACK (0078-1028-90)

Manufacturer / TM Owner

Novartis Pharmaceuticals Corporation

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

VIJOICE 125 mg/1 is primarily used in the treatment of specific medical conditions. It is often prescribed for patients who require targeted therapy to manage their symptoms. The medication works by affecting certain processes in the body to provide relief.

Side Effects

Common effects of VIJOICE 125 mg/1 may include gastrointestinal discomfort, fatigue, and changes in blood sugar levels. Some users may experience skin reactions or appetite changes. These effects can vary widely among individuals.

Precautions & Warnings

VIJOICE 125 mg/1 should be handled with care and stored as directed. It is important to follow the advice of a healthcare provider regarding its use. Patients should be aware of potential side effects and report any severe reactions promptly.

Avoid Interactions

VIJOICE 125 mg/1 may interact with certain medications, including those that affect liver enzymes. It is advisable to inform your healthcare provider about all medications you are taking to avoid potential interactions. Alcohol consumption should be discussed with a healthcare professional.

Frequently Asked Questions

VIJOICE 125 mg/1 is used to manage specific medical conditions, often in targeted therapy. It is important to consult a healthcare provider for personalized advice.

VIJOICE 125 mg/1 is taken orally, typically as directed by a healthcare provider. Always follow the prescribed dosage and instructions.

Common side effects may include gastrointestinal discomfort, fatigue, and changes in blood sugar levels. Severe reactions should be reported to a healthcare provider.

VIJOICE 125 mg/1 may interact with certain medications. It is important to discuss all current medications with a healthcare provider to avoid potential interactions.

VIJOICE 125 mg/1 should be stored as directed on the packaging, typically at room temperature and away from moisture and heat.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 28 Jul 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.